Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Sep
18
Today In Oncology
Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types
Study Finds Postapproval Cancer Trials Fell After Inflation Reduction Act
Incorporating Family Caregivers Into Shared Decision-Making for Patients With Cancer
Clear-Margin Diagnostic Excisional Biopsy May Adequately Treat Melanoma in Situ, Study Finds
Is TBI Associated With Malignant Brain Tumors
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo